



Published in final edited form as:  
*Mech Dev.* 2007 ; 124(9-10): 729–745.

## Concerted action of *Msx1* and *Msx2* in regulating cranial neural crest cell differentiation during frontal bone development

Jun Han<sup>1</sup>, Mamoru Ishii<sup>2</sup>, Pablo Bringas Jr.<sup>1</sup>, Richard L. Maas<sup>3</sup>, Robert E. Maxson Jr.<sup>2</sup>, and Yang Chai<sup>1,\*</sup>

<sup>1</sup> Center for Craniofacial Molecular Biology School of Dentistry University of Southern California, 2250 Alcazar Street, CSA 103, Los Angeles, CA 90033

<sup>2</sup> Department of Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center and Hospital, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089-9176

<sup>3</sup> Genetics Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115

### Abstract

The homeobox genes *Msx1* and *Msx2* function as transcriptional regulators that control cellular proliferation and differentiation during embryonic development. Mutations in the *Msx1* and *Msx2* genes in mice disrupt tissue-tissue interactions and cause multiple craniofacial malformations. Although *Msx1* and *Msx2* are both expressed throughout the entire development of the frontal bone, the frontal bone defect in *Msx1* or *Msx2* null mutants is rather mild, suggesting the possibility of functional compensation between *Msx1* and *Msx2* during early frontal bone development. To investigate this hypothesis, we generated *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. These double mutant embryos died at E17 to E18 with no formation of the frontal bone. There was no apparent defect in CNC migration into the presumptive frontal bone primordium, but differentiation of the frontal mesenchyme and establishment of the frontal primordium was defective, indicating that *Msx1* and *Msx2* genes are specifically required for osteogenesis in the cranial neural crest lineage within the frontal bone primordium. Mechanistically, our data suggest that *Msx* genes are critical for the expression of *Runx2* in the frontonasal subpopulation of cranial neural crest cells and for differentiation of the osteogenic lineage. This early function of the *Msx* genes is likely independent of the Bmp signaling pathway.

### Keywords

cranial neural crest (CNC) cells; frontal bone; *Msx1*; *Msx2*; *Runx2*; proliferation; differentiation; and apoptosis

---

(\* Corresponding Author: Dr. Yang Chai, Center for Craniofacial Molecular Biology, School of Dentistry, University of Southern California, 2250 Alcazar Street, CSA 103, Los Angeles, California, 90033, Tel. (323)442-3480, Fax (323)442-2981, email: ychai@usc.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Introduction

Frontal bones form the anterior aspect of the skull vault. During embryogenesis, cranial neural crest cells migrate into the presumptive frontal primordium, condense at the lateral aspect of the head and differentiate into osteoblasts, which constitute the frontal primordium. The primordium then proceeds to undergo apical extension and growth until adulthood. Meanwhile, the osteoblasts within the primordium synthesize bone matrix through intramembranous ossification (Couly et al., 1993; Jiang et al., 2002; Wilkie and Morriss-Kay, 2001). Extensive studies have been focused on the growth of frontal bones. Morriss-Kay and coworkers suggested that the development of the normal frontal bone must require mechanisms to ensure that both its morphology and its rate of growth are precisely matched to those of the developing brain (Iseki et al., 1999). This relationship is coordinated through tissue-tissue interactions between the brain, the developing meninges, the frontal bone primordium and the cranial sutures, the fibrous joint between two frontal bones (Antonopoulou et al., 2004; Holleville et al., 2003b; Ishii et al., 2003). However, the earliest aspect of frontal bone development, the initiation of osteogenesis in mesenchymal precursor cells, is largely unknown.

The CNC-derived ectomesenchyme is the sole source for populating the frontal bone primordium and its underlying meninges in mice (Jiang et al., 2002). The cranial neural crest (CNC) cells, a pluripotent cell population derived from the lateral ridges of the neural plate, migrate ventrolaterally to the frontonasal prominence and the branchial arches and give rise to the jaws, the anterior skull base and the anterior skull vault. The migration, proliferation and differentiation of CNC cells are regulated by growth factor signaling pathways and their downstream transcription factors before these cells become committed to an array of different phenotypes (Echelard et al., 1994; Graham and Lumsden, 1993; Lumsden, 1988; Noden, 1983; Trainor and Krumlauf, 2000). It is unknown, however, how the differentiation of osteoblasts is regulated in the CNC-derived cells. Understanding this event will shed light on the mechanism of lineage selection in the pluripotent precursors.

The homeobox genes *Msx1* and *Msx2* are highly conserved among various species and function as transcriptional regulators that control cellular proliferation and differentiation during normal embryonic development (Hill et al., 1989; Robert et al., 1989). *Msx1* is strongly expressed in CNC cells and plays a critical role in regulating epithelial-mesenchymal interactions during organogenesis (Hill et al., 1989; Lyons et al., 1992; Robert et al., 1989). Targeted null mutation of *Msx1* results in multiple craniofacial abnormalities including a frontal bone development defect (Satokata and Maas, 1994). *Msx2* null mutation causes pleiotropic defects in bone growth and ectodermal organ formation (Satokata et al., 2000). As the result of an osteoprogenitor proliferation defect, *Msx2* null mutant mice display defective skull ossification and persistent calvarial foramen, and the frontal primordium is reduced in size at the initiation stage of osteogenesis (Ishii et al., 2003), suggesting that *Msx2* plays a critical role in regulating calvarial morphogenesis. Significantly, the entire calvaria is missing in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant, suggesting that *Msx1* and *Msx2* function together to regulate osteogenesis during calvaria development (Satokata et al., 2000). The complete absence of the calvaria including the frontal bones provides a unique opportunity of explore the initiation of the frontal primordium. We hypothesize that *Msx1* and *Msx2* act concertedly to regulate the establishment of the frontal bone primordium. Taking advantage of the profound frontal bone defect in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos, we investigated the cellular and molecular mechanisms by which *Msx1* and *Msx2* function together to regulate the fate of CNC cells during frontal bone development.

Our study demonstrates that *Msx* genes are critical for osteogenic lineage differentiation of CNC cells during frontal primordium formation. *Msx* genes control osteogenesis by regulating *Runx2* expression. This study represents a significant step towards the understanding of the

molecular regulation of CNC fate determination and provides an animal model for the investigation of abnormal CNC development during calvarial morphogenesis.

## Results

### ***Msx1* and *Msx2* have critical and functionally redundant roles in regulating calvaria morphogenesis**

To test the hypothesis that *Msx1* and *Msx2* function redundantly to regulate calvaria morphogenesis, we generated double knockout mice. In *Msx1*<sup>-/-</sup>;*Msx2*<sup>+/-</sup> and *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> mice, the calvarial ossification defect between the frontal bones was significantly enlarged as compared to the *Msx1*<sup>-/-</sup> mutant (Fig. 1A,D,G,J arrows). In contrast, the fontanel between the parietal bones was comparable in *Msx1*<sup>-/-</sup>, *Msx1*<sup>-/-</sup>;*Msx2*<sup>+/-</sup>, and *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> mice (Fig. 1A,D,G,J \*). Thus, *Msx1* or *Msx2* null mutations in the background of haploinsufficiency of the complementary *Msx* gene significantly intensify the frontal ossification defects, whereas parietal bone development is largely unchanged. Next, we examined *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> double null mice and found that they were able to survive to E17 or E18 but showed no calvarial ossification with severely deformed craniobase and jaws (Fig. 1M–O). The only ossified bony elements in the skull were rudiments of mandible, maxilla and craniobase, although most of the cranial cartilage was present (Fig. 1M,N). The majority of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos (43/47=91%) had exencephaly and a partially open neural tube. To rule out the possibility that the frontal bone defect was solely associated with embryos that had an open neural tube, we investigated the frontal bone development in the *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> mice with open neural tubes (see Fig. 5). Our data suggest that *Msx1* and *Msx2* have important and concerted roles in the regulation of frontal bone development.

### ***Msx1* and *Msx2* are co-expressed in the presumptive frontal, but not parietal, primordium**

Unlike the gradient of defects detectable in the frontal bone, there is no obvious parietal bone defect in *Msx1*<sup>-/-</sup> or *Msx2*<sup>-/-</sup> mice (Fig. 1D,G,J \* versus arrow). To explore the possibility that *Msx1* and *Msx2* compensate for the function of each other completely during parietal bone development but only partially during frontal bone development, we documented the expression profiles of *Msx1* and *Msx2* in the presumptive primordium. Cranial skeletogenic mesenchyme derives from the mesoderm and neural crest. In the calvaria of mice, frontal bones are derived from cranial neural crest whereas parietal bones are derived from mesoderm (Jiang et al., 2002). These two embryonic origins can be mapped using the Cre/loxP system with LacZ as a reporter. At E10.5, all the CNC-derived mesenchyme in *Wnt1-Cre;R26R* mice are labeled with blue and condense in the frontonasal processes and the presumptive frontal primordium (Fig. 2A,B arrow), whereas the mesoderm-derived cells of *Mesp1-Cre/R26R* mice are stained blue and populate the future parietal primordium (Fig. 2A,B dotted line). Cells from these two origins are separated with a clear boundary. Interestingly, *Msx1* and *Msx2* were expressed only in the prospective frontal primordium (Fig. 1C–F arrow). There was no *Msx1* or *Msx2* expression in the prospective parietal primordium (Fig. 1C–F dotted line). At E12.5, both frontal and parietal primordia were well established, as indicated by alkaline phosphatase activity (Fig. 2G,I). *Msx1* is expressed only in the CNC-derived mesenchymal cells in the frontal bone primordium, not the parietal bone primordium (Fig. 2H,J,K,M,N arrows). *Msx2* was detectable in both the frontal and parietal primordia (Fig. 2L–P arrow). Thus, *Msx1* and *Msx2* were specifically co-expressed in the presumptive frontal bone primordium during calvaria development, suggesting possible concerted action in regulating the initiation of frontal bone development. In parietal bone development, however, there is no co-expression of *Msx1* and *Msx2* in the primordium and combined action is not likely to take place.

In addition to the divergent embryonic origins and differential expression of *Msx* genes, frontal and parietal primordia also vary in their rate of development. At E12.5, both primordia were

positive for alkaline phosphatase activity (Fig. 2Q), however we detected osteoblast differentiation markers, such as *Dlx5* and *Osterix*, only in the frontal primordium (Fig. 2R,S arrow). Subsequently, the frontal bone matrix developed faster than the parietal bone matrix (Fig. 2T,U).

### ***Msx1* and *Msx2* are required for frontal bone primordium formation during the initiation of calvarial morphogenesis**

The failure of frontal bone development in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice suggests that *Msx* genes may be specifically required for the initiation of frontal primordium morphogenesis. At E11.5, there is no clear mesenchymal condensation in wild type, *Msx1*<sup>-/-</sup> or *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> samples (Fig. 3A–C). At E12.5, the frontal bone primordium in wild type mice began to form as an aggregated cell mass above the developing orbit (Fig. 3D). This condensation of the CNC-derived mesenchyme prior to formation of the frontal bone is a critical step for normal development (Eames and Helms, 2004). In *Msx1* null mice, the frontal primordium was similar to that of wild type (Fig. 3E). There was no condensation of cells in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant (Fig. 3F). At E14.5, the frontal bone matrix began to form in both wild type and *Msx1* null mutant mice (Fig. 3G,H). There was some condensation of the CNC-derived cells in the frontal primordium of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant, but no bone matrix formation (Fig. 3I). By E16.5, frontal bone formation had extended towards the top of the calvaria in wild type mice (Fig. 3J). In *Msx1* null mutant mice, frontal bone development had extended apically to a lesser extent than wild type (Fig. 3K). No bone matrix was ever detected in the frontal bone primordium of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant with an open neural tube (Fig. 3L). This observation was later confirmed by bone differentiation marker analysis (see Fig. 5).

### **Loss of function of *Msx1* and *Msx2* does not affect the migration of CNC cells into the frontal primordium**

The frontal primordium is composed exclusively of cranial neural crest-derived mesenchyme. In order to test whether the malformations of the frontal bone in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> animals resulted from a CNC migration defect, we generated *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice carrying a *Wnt1cre;R26R* transgene (*Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup>;*Wnt1cre;R26R*). The phenotype of these embryos was indistinguishable from that of unmarked *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice (data not shown). We observed comparable β-gal staining in whole embryo preparations of wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> samples at both E9.5 and E10.5, suggesting normal CNC migration into the craniofacial region in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice (Fig. 4A–D and data not shown). At the cellular level, there was no apparent difference in the contribution of the CNC-derived cells between wild type, *Msx1*<sup>-/-</sup> and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. Specifically, the frontonasal neural crest was primarily concentrated in the region above the eye where the frontal primordium was developing and within the nasal swellings in the wild type sample at E10.5 (Fig. 4A,B). There was normal migration of CNC cells into the region above the eye in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant (Fig. 4C,D). After the formation of the frontal primordium at E12.5, there was also no apparent difference in the distribution of CNC cells within the frontal primordium between wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. CNC-derived cells condensed in a region dorsal to the developing eye where the frontal primordium was forming (Fig. 4E arrow). In the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant, there was no obvious deficiency of CNC-derived cells in the region of the frontal bone primordium (Fig. 4F). Taken together, our data indicate that a CNC migration defect was not responsible for the failure of frontal bone formation in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice.

## CNC-derived mesenchymal precursors in the frontal bone region fail to differentiate into the osteogenic lineage

In mouse calvaria morphogenesis, a well-defined frontal primordium is visible at E12.5 with the expression of alkaline phosphatase and osteogenic lineage markers such as *Fgfr2*, *Dlx5*, *Runx2*, and *Osterix* in the CNC-derived mesenchymal cells (Fig. 5A–E). In *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* embryos, however, there is no expression of any of these osteogenic markers in the frontal primordium region (Fig. 5F–J). The CNC-derived frontal mesenchymal cells failed to express osteogenic lineage genes known to be critical for calvarial development at E14.5 (Fig. 5P–T) and E16.5 (Fig. 5Z) as well. Thus, our results strongly suggest that the CNC-derived mesenchymal precursors in the frontal bone region failed to commit into the osteogenic lineage.

*Fgfr2* is a critical regulator for osteoprogenitor cell proliferation during frontal bone development (Iseki et al., 1999). Recent study shows that *Fgfr2*-deficient mice have bone development defects resulting from a decrease in osteoblast proliferation (Yu et al., 2003). To test whether *Fgfr2* acts downstream of *Msx* signaling, we compared the expression of *Fgfr2* in wild type and *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant mice. In *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mice, expression of *Fgfr2* in the presumptive frontal primordium was lost, whereas the expression of *Fgfr2* in the brain and surface epithelium remained comparable to the wild type littermate control (Fig. 5B,G). This specific absence of *Fgfr2* expression corresponds with the region of specific co-expression of *Msx1* and *Msx2* in the presumptive primordium. This loss of *Fgfr2* expression was also detected in the frontal primordium region of the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant at E14.5 (Fig. 5L,Q), again not in the brain and surface epithelium.

Next, we analyzed the expression of *Dlx5*, a critical mediator for calvarial osteoblast differentiation. Loss of *Dlx5* results in multiple craniofacial defects including malformed frontal bones (Acampora et al., 1999; Depew et al., 1999; Holleville et al., 2003a; Tadic et al., 2002). In vitro, *Msx* and *Dlx5* are expressed at different stages of osteoblast differentiation (Ryoo et al., 1997) and *Msx* and *Dlx5* can form heterodimers and regulate the promoter of the osteogenic lineage markers, *Osteocalcin* (Newberry et al., 1998; Zhang et al., 1997). To determine the effect of loss of both *Msx1* and *Msx2* on the expression of *Dlx5* during the differentiation of the CNC-derived frontal mesenchymal precursors, we examined the expression of *Dlx5* in wild type and *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mice. At E12.5, we detected no *Dlx5* expression in the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant presumptive frontal primordium, although well-defined *Dlx5* expression was present within the frontal primordium of the control sample (Fig. 5C,H). However, similar *Dlx5* expression in the brain was detected in both the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mice and the control (data not shown). At E14.5, we also did not detect *Dlx5* expression in the frontal primordium of the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant, although expression in the brain was comparable in both the control and *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mice (Fig. 5M,R).

Finally, we examined the expression of osteogenic-lineage specific markers *Runx2* and *Osterix* in the frontal primordium to determine if an osteoprogenitor differentiation defect might be responsible for the failure of frontal primordium initiation in the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant. *Runx2*, a runt-domain transcription factor, is expressed initially in the mesenchymal condensations of the developing skeleton, and the expression is strictly restricted to cells of the osteoblast lineage (Ducy et al., 1997). *Osterix*, a zinc finger-containing transcription factor, is expressed in the osteoblasts of all bones (Nakashima et al., 2002). Both *Runx2* and *Osterix* are required for osteoblast differentiation and osteogenesis in neural crest and mesoderm derived bones (Komori et al., 1997; Nakashima et al., 2002). By E12.5, both *Runx2* and *Osterix* were expressed in the frontal primordium of the wild type samples, whereas neither were detected in the presumptive frontal primordium of the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mutant (Fig. 5D,E,I,J). Neither *Runx2* or *Osterix* expression was detected in the frontal primordium region



of *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice at E14.5 (Fig. 5S,T), suggesting a failure in osteogenesis. In contrast, the expression of both *Runx2* and *Osterix* was expanded in wild type mice at E14.5 (Fig. 5N,O).

The anterior neural pore failed to close in the majority of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutants. The failure of osteoblast differentiation in the frontal primordium could be the result of exencephaly. However, our data suggest the contrary. A small number of *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> mice (3 out of 240) were born with exencephaly. In these mice, apical extension of frontal bone is abolished but the CNC-derived frontal mesenchymal cells were able to differentiate into osteoblasts and form the orbital portion of the frontal bone at E16.5 (Fig. 5U,V). In contrast, the orbital portion of the frontal bone is missing in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice at E16.5, along with the rest of the frontal bone (Fig. 5X,Y). In *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> mice with exencephaly, the osteogenic lineage differentiation marker alkaline phosphatase can be detected at E12.5 (Fig. 5W). In *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice, we detected no alkaline phosphatase activity in the CNC-derived mesenchymal cells in the frontal primordium at E12.5 or E14.5 (Fig. 5F,P). The alkaline phosphatase staining of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice was ambiguous in the frontal region at E16.5 (Fig. 5Z), but *in situ* failed to detect osteogenic lineage specific markers such as *Runx2* and *Osterix* (data not shown). Due to the scarcity of the exencephalic *Msx1*<sup>+/-</sup>;*Msx2*<sup>-/-</sup> samples, we did not document the expression of osteogenic lineage markers in this group.

### Increased cell density fails to promote osteogenesis in the cultured CNC-derived frontal primordium of *Msx1*<sup>-/-</sup>/*Msx2*<sup>-/-</sup> mice

In order to distinguish whether the differentiation defect of the CNC-derived frontal mesenchyme was the result of an intrinsic requirement for the *Msx* genes or a failure of CNC aggregation in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant with an open neural tube, we cultured these cells under an artificial high density (micromass) or monolayer condition. We dissected E11.5 presumptive frontal bone primordium from wild type and *Msx1*<sup>-/-</sup>/*Msx2*<sup>-/-</sup> mutant embryos. Following twelve days of culture, an examination of the micromass cultures revealed nodule formation in wild type, *Msx1*<sup>-/-</sup>, *Msx2*<sup>-/-</sup> and the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant samples (Fig. 6A–D). We were able to detect cartilage and bone formation in the wild type, *Msx1*<sup>-/-</sup>, and *Msx2*<sup>-/-</sup> samples (Fig. 6E–G). Histological analysis confirmed the presence of alcian blue-positive cartilage structures with typical chondrocytes and compact, trabecular-like structures (Fig. 6I–K). We also detected deposits of calcium in wild type, *Msx1*<sup>-/-</sup>, and *Msx2*<sup>-/-</sup> samples (Fig. 6M–O), but not in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> sample (Fig. 6P). In the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant, however, there was no indication of bone or cartilage development (Fig. 6H). Cross-section analysis showed that these cultured CNC cells failed to organize into any structure that resembles cartilage or bone (Fig. 6L). In addition, cultured frontal primordium CNC cells grown in a monolayer were able to express alkaline phosphatase in the wild type, *Msx1*<sup>-/-</sup>, and *Msx2*<sup>-/-</sup> samples, confirming the successful differentiation of CNC into osteoblasts (Fig. 6Q–S). In contrast, there was no detectable alkaline phosphatase expression in cultured *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> CNC cells, indicating a failure of osteoblast differentiation (Fig. 6T). Taken together, our data suggest that there is an intrinsic requirement for *Msx1* and *Msx2* in the CNC-derived frontal bone primordium.

### Ectopic *Runx2* restores osteogenic differentiation of the frontal CNC cells

The failure of CNC-derived frontal mesenchymal cells to differentiate into osteogenic lineage and to express osteogenic lineage specific transcription factor *Runx2* suggested that *Runx2* may function downstream of *Msx1* and *Msx2* to promote the osteogenic differentiation of the CNC-derived frontal mesenchyme. To test this hypothesis, we transfected *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> frontal mesenchymal cells with a *Runx2*-expressing vector and examined osteogenic differentiation using alkaline phosphatase activity as marker. We detected the expression of GFP and *Runx2* in transfected wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> cells (Fig. 7A–C, G). Upon the

ectopic expression of *Runx2*, *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> cells expressed alkaline phosphatase at a level comparable to that of the wild type control, whereas the negative control, *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> cells treated with empty vector, remained unstained. (Fig. 7D–F).

### BMP signaling pathway during frontal primordium establishment

*Msx* genes have been reported to regulate the expression of *Bmp* genes (Bei et al., 2000; Brugger et al., 2004). To investigate whether an alteration in the BMP signaling pathway is responsible for the failure of differentiation of the CNC cells within the frontal primordium, we surveyed the expression of *Bmp2*, *Bmp4*, and *Bmp7* after CNC migration and before the establishment of the primordium in wild type samples (Fig. 8A–L). Of these, *Bmp4* is the only *Bmp* actively expressed in the presumptive primordium (Fig. 8E–H, arrow). *Bmp* expression in hair follicles (Fig. 8F,G) and in the midbrain served as positive controls (Fig. 8E–H). *Bmp2* and *Bmp7* were expressed in hair follicles (Fig. 8B,C,J,K), but were absent from the frontal primordium (Fig. 8D,L).

Surprisingly, the expression of *Bmp4* in the presumptive frontal primordium persisted in the *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> samples. The expression of *Bmp4* in wild type, *Msx1*<sup>-/-</sup>, *Msx2*<sup>-/-</sup>, and *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> samples was indistinguishable (Fig. 8M–Q). To support this finding, we analyzed the phosphorylation state of the pan-Bmp Smads. In wild type, *Msx1*<sup>-/-</sup>, *Msx2*<sup>-/-</sup>, and *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> samples, we also detected the phosphorylation and nuclear translocation of BMP Smads, a result consistent with the maintenance of BMP4 signaling (Fig. 8R–V).

## Discussion

### *Msx* genes function in calvarial development

One intriguing feature of the calvarial phenotype associated with *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mice is the absence of parietal as well as frontal bones. However, we conclude that the parietal bone defect is not a direct result of the loss of function of *Msx1* and *Msx2*. First, neither *Msx1* nor *Msx2* is expressed in the mesoderm that gives rise to the parietal primordium. In the parietal primordium, *Msx2* is only expressed when osteogenic differentiation is visible, while *Msx1* is absent throughout the early parietal bone development. In addition, skeletal staining of newborn samples shows that there is no obvious parietal bone defect in single *Msx* mutants (Fig. 1), consistent with previous reports on *Msx1*<sup>-/-</sup> or *Msx2*<sup>-/-</sup> mice. Frontal bones are the only component of the skull vault that suffered developmental defects in both *Msx1* and *Msx2* null mutant mice. In *Msx1*<sup>-/-</sup> mice, a deficiency of the medial portions of the frontal bones results in an enlarged anterior fontanel. In the parietal bone, there are no osteogenic defects, other than that a small region of the parietal bones overlaps (Satokata and Maas, 1994). *Msx2*<sup>-/-</sup> mice have an enlarged anterior fontanel at E18.5, indicating that frontal bone ossification is delayed. In contrast, the parietal fontanel is similarly sized in wild type and *Msx2*<sup>-/-</sup> mice even though the interparietal and supraoccipital bones are small and abnormally shaped (Satokata et al., 2000). We also found that the parietal fontanel in *Msx1*<sup>+/-</sup>; *Msx2*<sup>-/-</sup> and *Msx1*<sup>-/-</sup>; *Msx2*<sup>+/-</sup> mice are comparable that of wild type, whereas the frontal fontanel were greatly enlarged.

Thus, the parietal bone defects in *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mice are likely secondary to those of the cranial neural crest cells, possibly as a result of compromised CNC-derived meninges, as this interaction is required for parietal ossification (Jiang et al., 2002). Conditional inactivation of *Tgfb2* in the neural crest cells leads to compromised parietal development, as a result of defective meninges (Ito et al., 2003). In further support of this hypothesis, the expansion of CNC cells toward the apical midline is limited in *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mice (Fig. 4F), suggesting a meninges defect. Unfortunately, markers for the early development of meninges have not been identified and most *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mutants die before E16.5, so the meninges defect

and the function of meninges during parietal bone development still requires further investigation. Meanwhile, the function of meninges during the development of frontal bone also needs to be addressed using other conditional gene targeting approaches.

### The function of *Msx* genes in CNC cell induction and migration

The frontonasal skeleton derives from rostral cranial neural crest cells, which arise from the diencephalon and midbrain (Santagati and Rijli, 2003). The failure of frontal bone early development could be a result of aberrant CNC cells induction or migration given the fact that the expression patterns of the *Msx* genes are closely related to the development of neural crest cells in several species. In mammals, the early expression of *Msx1* and *Msx2* demarcates the area from which neural crest cells emigrate (Hill et al., 1989; Mackenzie et al., 1991). Expression of *Msx1* and *Msx2* in the cranial neural crest continues during cell migration and colonization of the branchial arches (Catron et al., 1996; MacKenzie et al., 1992). Furthermore, forced expression of *Msx1* in *Xenopus* embryos induces neural crest cells, and inhibition of *Msx1* activity by dominant negative *Msx1* inhibits the production of neural crest cells (Tribulo et al., 2003). In *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice, there are defects in the specification or distribution of subpopulations of cranial neural crest cells. Reduced β-galactosidase staining was evident in the stream of neural crest from rhombomere 6 and 7 in *Wnt1-Cre;R26R;Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice (Ishii et al., 2005). Our data suggests that CNC migration into the frontal bone primordium is unaffected in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. Post-migratory CNC cells survived until the differentiation stages. One explanation for the lack of a neural crest induction defect may be functional redundancy of *Msx1* and *Msx2* with the remaining member of the *Msx* gene family, *Msx3*, which is expressed within the neural tube. However, the rostral boundary of *Msx3* expression is the rhombencephalon (Wang et al., 1996), whereas the frontal bone-contributing CNC cells derive from prosencephalon and mesencephalon. Therefore, the expression patterns of the three *Msx* genes are not consistent with an argument for functional overlap. In addition, *Msx1* and *Msx3* execute distinct functions in the neural tube when overexpressed (Liu et al., 2004). We consider it unlikely that *Msx3* compensates for the loss of *Msx1* and *Msx2* function. Another possibility is that the *Msx* gene family is not necessary for the formation and migration of cranial neural crest cells destined to populate the frontonasal process, but is instead involved in survival, proliferation and differentiation during and/or after migration. This model was also confirmed by previous work (Ishii et al., 2005).

### *Msx* genes control CNC-derived osteoblast differentiation in the frontal primordium

The compromised frontal bone primordium and the failure of the frontal mesenchyme to express *Runx2* in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos suggests that *Msx* genes are critical for the differentiation of post-migratory CNC cells into the osteogenic lineage. This differentiation defect is not secondary to the loss of CNC-derived cells within the presumptive primordium because our cell fate mapping data from *Wnt1-Cre;R26R;Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice reveals a comparable contribution from CNC-derived mesenchymal cells (see Fig. 4E,F). The differentiation defect is not due to the failure in neural tube closure either, because the orbital portion of the frontal bone is formed in *Msx1*<sup>+/-</sup>;*Msx2*<sup>+/-</sup> embryos with exencephaly and the differentiation of post-migratory CNC cells followed the same temporal pattern as the wild type control (see Fig. 6). Reduced cell proliferation and condensation cannot explain the differentiation defect either, because culturing the E11.5 mesenchymal cells from the putative frontal primordium in an artificially high cell density failed to rescue the defect. Osteogenic culture condition failed to induce the differentiation in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> cells either, so the defect is more likely to be intrinsic.

The rudimentary maxilla and mandible present in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice appear to contradict a model positing the intrinsic requirement of *Msx1* and *Msx2* function for osteogenic lineage differentiation in all CNC cells. However, the maxilla and mandible are derived from



neural crest cells originating in the hindbrain, whereas the frontal and nasal bone are derived from neural crest cells originating from forebrain and midbrain (Helms and Schneider, 2003). Thus, bones derived from the first branchial arch are partly formed in the absence of *Msx1* and *Msx2*, but bones derived from the frontonasal process fail to form, suggesting that there may be an intrinsic requirement for *Msx1* and *Msx2* function during osteoblast differentiation in the frontonasal process-derived bones but not in the branchial-arch derived bones. It is also possible that *Msx1* and *Msx2* control some inductive step(s) in calvaria morphogenesis that is different from the mechanism involved in osteogenesis in jaws. More detailed studies on the tissue-tissue interaction during the establishment of the frontal bone primordium might shed light on this issue.

Multiple studies have addressed the function of *Msx* genes in osteogenesis (Cheng et al., 2003; Satokata et al., 2000; Shirakabe et al., 2001), but their conclusions have not been consistent. For example, stable, forced *Msx2* expression in MC3T3E1 cells prevented osteoblast differentiation and matrix mineralization (Yoshizawa et al., 2004), but viral *Msx2* induced osteogenic differentiation in the aortic myofibroblast (Cheng et al., 2003). The variation of cell types and developmental stages might contribute to the differences observed in the function of *Msx* genes in osteogenesis. Most reported functions of *Msx* genes have derived from studies in committed progenitor cells, although the expression of *Msx* genes occurs prior to the appearance of the osteoprogenitors. Limited study has been focused on the function of the *Msx* genes in the initiation of the frontal primordium. Null mutation of *Msx2* leads to a reduction in size of the frontal primordium (Ishii et al., 2003). Early differentiation markers, such as alkaline phosphatase and *Runx2*, were expressed in *Msx2*<sup>-/-</sup> mice with the same temporal pattern as wild type although the expression domain is reduced in size, suggesting that the CNC cells are competent to differentiate into the osteogenic lineage in the absence of *Msx2* (Ishii et al., 2003). In contrast, *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice completely lack *Runx2* and *Osterix* expression in the frontal primordium, providing the first *in vivo* evidence for the requirement of *Msx* genes in the differentiation of the CNC-derived frontal mesenchymal cells into the osteogenic lineage. *Msx2* has been shown to induce alkaline phosphatase activity and promote calcification in *Runx2*-deficient mice (Cheng et al., 2003; Ichida et al., 2004). It is possible that *Msx* genes promote osteoblast differentiation in both *Runx2*-dependent and *Runx2*-independent manners.

### ***Msx* genes are critical for the expression of *Runx2* in the frontal primordium**

The failure of CNC-derived mesenchymal cells to express *Runx2* and *Osterix* in the absence of *Msx1* and *Msx2* may prevent osteogenic differentiation. *Runx2* is an essential transcription factor controlling osteoblast differentiation. Null mutation of *Runx2* leads to a complete lack of ossification in both neural crest and mesoderm derived bones (Komori et al., 1997). In primary bone marrow stromal cells, exogenous *Runx2* expression enhances *in vitro* osteoblastic differentiation and mineralization (Byers and Garcia, 2004). We have shown above that the ectopic expression of *Runx2* in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> frontal mesenchyme partially restored the differentiation of CNC-derived cells into osteogenic lineage, based on alkaline phosphatase activity. The partial rescue of differentiation may be due to incomplete transfection efficiency or to a requirement for additional factors. Previously, *Msx2* has been reported to promote osteoblast differentiation independent of *Runx2* (Ichida et al., 2004). Expression of *Runx2* with a stably-expressing cell line or virus transfection with efficiency over 90% might help resolve this issue in the future. Nevertheless, our data suggests that *Runx2* mediates the effect of *Msx1* and *Msx2* on the differentiation of CNC-derived frontal mesenchyme into the osteogenic lineage. However, to date, there is no evidence for a direct interaction of *Msx* with the *Runx2* promoter (Otto et al., 2003). It is also possible that *Msx* genes regulate *Runx2* expression indirectly through a network of other factors.

*Osterix* is expressed in all developing bones and the mesenchyme of membranous bones which failed to differentiate into osteoblasts in *Osterix* null mutant (Nakashima et al., 2002). However, the stable expression of *Osterix* in fibroblasts is not sufficient for osteogenic lineage commitment. Forced expression of *Osterix* stimulates osteopontin expression but not the activity of alkaline phosphatase or the expression of *Collagen type I* and *Osteonectin* (Kim et al., 2006). *Osterix* is not expressed in *Runx2* null mutant mice, but *Runx2* is expressed in *Osterix* null mutant mice (Nakashima et al., 2002). Also, the *Osterix* promoter contains putative binding sites for *Msx2* and *Runx2*. Both *Msx2* and *Runx2* mildly increase *Osterix* promoter activity (Lu et al., 2006). *Osterix* likely functions downstream of *Runx2*.

### **Msx genes control the differentiation of frontal CNC cells through signaling pathways other than BMP**

BMPs function as one of the important regulators of *Msx* genes (Brugger et al., 2004) (Tribulo et al., 2003) (Zhang et al., 2003b). Both *Msx1* and *Msx2* can be induced by BMP4 during early tooth and suture development (Bei and Maas, 1998; Kim et al., 1998). Interestingly, *Msx* can also function to regulate *Bmp* expression in tooth development and digit regeneration (Bei et al., 2000; Bei and Maas, 1998; Han et al., 2003). BMPs have been also associated with the formation, migration, and differentiation of neural crest cells and skeletal morphogenesis (Barembaum and Bronner-Fraser, 2005; Goldstein et al., 2005; Kanzler et al., 2000; Kleber et al., 2005; Mbalaviele et al., 2005). However, it has been difficult to determine the function of BMP signaling in osteogenesis using individual *Bmp* deficient mice. Most *Bmp* knockout mice exhibit mortality too early to detect skull defects (Chen et al., 2004; Winnier et al., 1995; Zhang and Bradley, 1996). Others show no obvious skull defects (Kingsley et al., 1992; Solloway et al., 1998; Yan et al., 2001) or produce an increase in bone density (Daluisi et al., 2001). However, *Bmp1* deficient mice suffer reduced ossification of frontal, parietal, and interparietal bones (Suzuki et al., 1996) and *Bmp7* knockout mice have a skull patterning defect (Luo et al., 1995).

BMP4 has been reported to be involved in intramembranous bone growth. Exogenous BMP4 can increase tissue volume in calvarial culture, but does not accelerate osteogenic differentiation (Kim et al., 1998). In hematopoietic stem cells, conditional inactivation of *Bmpr1a* leads to an increase in the number of osteoblastic cells (Zhang et al., 2003a). Based on the comparable BMP signaling activity in the presumptive frontal primordium of *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* mice (see Figure 8) and the persistence of *Bmp4* expression in the first branchial arch (Ishii et al., 2005), we conclude that *Bmp* signaling is not likely required for osteogenic lineage differentiation in the frontal primordium. Due to the functional redundancy among BMPs and the early lethality of *Bmp2;Bmp4* or *Bmp5;Bmp7* double knockout mice, we have not been able to compare the calvarial phenotypes of compound *Bmp* and *Msx* mutants.

The reduced *Fgfr2* expression within the frontal primordium in the *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* samples suggests that FGF signaling might be compromised. In humans, gain-of-function mutations in *FGFR1*, *FGFR2*, *FGFR3*, and *MSX2* are linked to craniosynostoses (Cohen, 1997; Jabs et al., 1994; Jabs et al., 1993; Lomri et al., 1998; Muenke et al., 1997). In mice, however, inactivation of *Fgf* genes leads either to lethality too early to allow analysis of frontal primordium development (Arman et al., 1998; Deng et al., 1994; Feldman et al., 1995; Meyers et al., 1998) or to no obvious skull defects (Colvin et al., 1996; Hebert et al., 1994; Min et al., 1998; Ortega et al., 1998). However, there is evidence that FGF signaling is involved in calvarial development. In calvarial culture, FGF4 accelerates the ossification of the suture and induces its early closure (Kim et al., 1998). FGF2 can rescue the compromised osteogenic proliferation of *Tgfr2* conditional knockout mice (Sasaki et al., 2006).

Other signaling pathways such as *TGF-β*, *Wnt* and *Hh* have also been shown to be important in regulating bone formation (Gaur et al., 2005; Ito et al., 2003; Mansukhani et al., 2000).

However Shh and its receptor, Ptc, are not expressed during the initial establishment of the frontal primordium (Kim et al., 1998). Previous studies have suggested that Wnt signaling may be involved in osteogenesis in long bone development or cell lines, but the role of Wnt in skull development remains unclear (Hu et al., 2005; Monkley et al., 1996; Spencer et al., 2006).

In conclusion, we have shown that *Msx1* and *Msx2* act in concert to regulate the establishment of the CNC-derived frontal bone primordium. Moreover, *Msx* genes act upstream of *Runx2* to control osteogenesis during the development of the frontal bone primordium.

## Experimental Procedures

### Animals and tissue preparation

We generated *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice carrying the *Wnt1cre;R26R* transgene by crossing *Wnt1cre*<sup>Tg/+</sup>;*Msx1*<sup>+/-</sup>;*Msx2*<sup>+/-</sup> with *R26R*<sup>Tg/+</sup>;*Msx1*<sup>+/-</sup>;*Msx2*<sup>+/-</sup> mice. Embryonic age was determined as previously described (Theiler, 1989). Genotyping was performed as described previously (Chai et al., 2000; Saga et al., 1999; Satokata et al., 2000; Satokata and Maas, 1994; Soriano, 1999).

### Detection of $\beta$ -galactosidase (*lacZ*) activities

Whole embryos (E10.5) or frozen sectioned tissues were stained for  $\beta$ -galactosidase activity according to standard procedures (Chai et al., 2000)

### Histology, skeleton staining and in situ hybridization

Histological analysis and whole mount skeleton staining of wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> samples were carried out as previously described (Ito et al., 2003). In situ hybridization was performed according to standard procedures (Xu et al., 2005).

### Micromass and monolayer cell culture

The frontal bone primordium tissue block above the eye was dissected and removed from wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos at E11.5. Cells were dissociated in dissociation buffer (0.1% collagenase, 0.1% trypsin EDTA in DPBS) for 15 minutes at 37°C. Dissociated cells were pipetted into single cell suspension and plated at a concentration of  $3.5 \times 10^6$  cells/ml in a 96-well plate in micromass culture medium (36% DMEM high glucose with pyruvate, 54% F12, 10% FCS, 50  $\mu$ g/ml ascorbic acid) for 6 days. From day 7 to day 12, cultures were maintained in mineralization medium (50  $\mu$ g/ml ascorbic acid, 10mM  $\beta$ -glycerophosphate in  $\alpha$ -MEM) and terminated on day 12. For monolayer cell culture, cells were plated at  $5 \times 10^3$  cells/ml in mineralization medium (10% FBS, 50  $\mu$ g/ml ascorbic acid, 10mM  $\beta$ -glycerophosphate in  $\alpha$ -MEM) for 7 days.

### Constructs and transfection

pGFP-C1 vector, *Runx2* cDNA were kindly given by Dr. Baruch Frenkel. The sequences of the constructs were confirmed by DNA sequence analysis. The empty pCMV5 vector was used as control. Transfection of primary frontal primordium mesenchymal cells was carried out using Lipofectmin 2000 (Invitrogen) according to the manufacturer's protocol. Cells were transfected 3 days after plating and were harvested at day 8.

### Quantitative PCR analysis

Total RNA from the cultured cells were extracted using RNeasy mini kit and treated with RNase-free DNase I (Qiagen) following the manufacturer's protocol. The Superscript III with an oligo(dT)<sub>20</sub> primer (Invitrogen) was used for the first-strand synthesis. We carried out real-time RT-PCR on the iCycler (Bio-rad) with gene-specific primers and using SYBR Green. All

reactions were under the following cycling protocol: 3 min heat start at 95°C and 40 cycles of denaturation at 95°C for 1 min, annealing and extension at 60°C for 1 min. We normalized relative expression ratios to  $\beta$ -actin. Primer sequences are available on request.

### Acknowledgements

We thank Dr. Julie Mayo for critical reading of the manuscript. This study was supported by grants from the National Institute of Dental and Craniofacial Research, NIH (DE012711, and DE017007) and March of Dime Birth Defects foundation to Yang Chai.

### References

- Acampora D, Merlo GR, Paleari L, Zerega B, Postiglione MP, Mantero S, Bober E, Barbieri O, Simeone A, Levi G. Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene *Dlx5*. *Development* 1999;126:3795–809. [PubMed: 10433909]
- Antonopoulou I, Mavrogiannis LA, Wilkie AO, Morriss-Kay GM. *Alx4* and *Msx2* play phenotypically similar and additive roles in skull vault differentiation. *J Anat* 2004;204:487–99. [PubMed: 15198690]
- Arman E, Haffner-Krausz R, Chen Y, Heath JK, Lonai P. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. *Proc Natl Acad Sci U S A* 1998;95:5082–7. [PubMed: 9560232]
- Barembaum M, Bronner-Fraser M. Early steps in neural crest specification. *Semin Cell Dev Biol*. 2005
- Bei M, Kratochwil K, Maas RL. BMP4 rescues a non-cell-autonomous function of *Msx1* in tooth development. *Development* 2000;127:4711–8. [PubMed: 11023873]
- Bei M, Maas R. FGFs and BMP4 induce both *Msx1*-independent and *Msx1*-dependent signaling pathways in early tooth development. *Development* 1998;125:4325–33. [PubMed: 9753686]
- Brugger SM, Merrill AE, Torres-Vazquez J, Wu N, Ting MC, Cho JY, Dobias SL, Yi SE, Lyons K, Bell JR, Arora K, Warrior R, Maxson R. A phylogenetically conserved cis-regulatory module in the *Msx2* promoter is sufficient for BMP-dependent transcription in murine and *Drosophila* embryos. *Development* 2004;131:5153–65. [PubMed: 15459107]
- Byers BA, Garcia AJ. Exogenous *Runx2* expression enhances in vitro osteoblastic differentiation and mineralization in primary bone marrow stromal cells. *Tissue Eng* 2004;10:1623–32. [PubMed: 15684671]
- Catron KM, Wang H, Hu G, Shen MM, Abate-Shen C. Comparison of *MSX-1* and *MSX-2* suggests a molecular basis for functional redundancy. *Mech Dev* 1996;55:185–199. [PubMed: 8861098]
- Chai Y, Jiang X, Ito Y, Bringas P, Han J, Rowitch D, Soriano P, McMahon A, Sucov H. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. *Development* 2000;127:1671–1679. [PubMed: 10725243]
- Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, Conway SJ, Yoder MC, Haneline LS, Franco D, Shou W. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. *Development* 2004;131:2219–31. [PubMed: 15073151]
- Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. *MSX2* promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. *J Biol Chem* 2003;278:45969–77. [PubMed: 12925529]
- Cohen MM Jr. Transforming growth factor beta s and fibroblast growth factors and their receptors: role in sutural biology and craniosynostosis. *J Bone Miner Res* 1997;12:322–31. [PubMed: 9076574]
- Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat Genet* 1996;12:390–7. [PubMed: 8630492]
- Couly GF, Coltey PM, Le Douarin NM. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. *Development* 1993;117:409–29. [PubMed: 8330517]
- Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM. Bone morphogenetic protein-3 is a negative regulator of bone density. *Nat Genet* 2001;27:84–8. [PubMed: 11138004]
- Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM, Leder P. Murine FGFR-1 is required for early postimplantation growth and axial organization. *Genes Dev* 1994;8:3045–57. [PubMed: 8001823]


- Depew M, Liu J, Long J, Presley R, Meneses J, Pedersen R, Rubenstein J. *Dlx5* regulates regional development of the branchial arches and sensory capsules. *Development* 1999;126:3831–3846. [PubMed: 10433912]
- Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* 1997;89:747–54. [PubMed: 9182762]
- Eames BF, Helms JA. Conserved molecular program regulating cranial and appendicular skeletogenesis. *Dev Dyn* 2004;231:4–13. [PubMed: 15305282]
- Echelard Y, Vassileva G, McMahon AP. Cis-acting regulatory sequences governing *Wnt-1* expression in the developing mouse CNS. *Development* 1994;120:2213–24. [PubMed: 7925022]
- Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, Goldfarb M. Requirement of FGF-4 for postimplantation mouse development. *Science* 1995;267:246–9. [PubMed: 7809630]
- Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Canonical WNT signaling promotes osteogenesis by directly stimulating *RUNX2* gene expression. *J Biol Chem* 2005;280:33132–40. [PubMed: 16043491]
- Goldstein AM, Brewer KC, Doyle AM, Nagy N, Roberts DJ. BMP signaling is necessary for neural crest cell migration and ganglion formation in the enteric nervous system. *Mech Dev* 2005;122:821–33. [PubMed: 15905074]
- Graham A, Lumsden A. The role of segmentation in the development of the branchial region of higher vertebrate embryos. *Birth Defects Orig Artic Ser* 1993;29:103–12. [PubMed: 8280868]
- Han M, Yang X, Farrington JE, Muneoka K. Digit regeneration is regulated by *Msx1* and *BMP4* in fetal mice. *Development* 2003;130:5123–32. [PubMed: 12944425]
- Hebert JM, Rosenquist T, Gotz J, Martin GR. *FGF5* as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. *Cell* 1994;78:1017–25. [PubMed: 7923352]
- Helms JA, Schneider RA. Cranial skeletal biology. *Nature* 2003;423:326–31. [PubMed: 12748650]
- Hill R, Jones P, Rees A, Sime C, Justice M, Copeland N, Jenkins N, Graham E, Davidson D. A new family of mouse homeo box-containing genes: molecular structure, chromosomal location, and developmental expression of *Hox-7.1*. *Genes Dev* 1989;3:26–37. [PubMed: 2565278]
- Holleville N, Quilhac A, Bontoux M, Monsoro-Burq A-He. BMP signals regulate *Dlx5* during early avian skull development. *Developmental Biology* 2003a;257:177–189. [PubMed: 12710966]
- Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH. BMP signals regulate *Dlx5* during early avian skull development. *Dev Biol* 2003b;257:177–89. [PubMed: 12710966]
- Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. *Development* 2005;132:49–60. [PubMed: 15576404]
- Ichida F, Nishimura R, Hata K, Matsubara T, Ikeda F, Hisada K, Yatani H, Cao X, Komori T, Yamaguchi A, Yoneda T. Reciprocal roles of *MSX2* in regulation of osteoblast and adipocyte differentiation. *J Biol Chem* 2004;279:34015–22. [PubMed: 15175325]
- Iseki S, Wilkie AO, Morriss-Kay GM. *Fgfr1* and *Fgfr2* have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. *Development* 1999;126:5611–20. [PubMed: 10572038]
- Ishii M, Han J, Yen HY, Sucov HM, Chai Y, Maxson RE Jr. Combined deficiencies of *Msx1* and *Msx2* cause impaired patterning and survival of the cranial neural crest. *Development* 2005;132:4937–50. [PubMed: 16221730]
- Ishii M, Merrill AE, Chan YS, Gitelman I, Rice DP, Sucov HM, Maxson RE Jr. *Msx2* and *Twist* cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault. *Development* 2003;130:6131–42. [PubMed: 14597577]
- Ito Y, Yeo JY, Chytil A, Han J, Bringas P Jr, Nakajima A, Shuler CF, Moses HL, Chai Y. Conditional inactivation of *Tgfr2* in cranial neural crest causes cleft palate and calvaria defects. *Development* 2003;130:5269–80. [PubMed: 12975342]
- Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR, Jackson CE, Jaye M. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. *Nat Genet* 1994;8:275–9. [PubMed: 7874170]
- Jabs EW, Muller U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Mulliken JB, et al. A mutation in the homeodomain of the human *MSX2* gene in a family affected with autosomal dominant craniosynostosis. *Cell* 1993;75:443–50. [PubMed: 8106171]



- Jiang X, Iseki S, Maxson RE, Sucov HM, Morriss-Kay GM. Tissue origins and interactions in the mammalian skull vault. *Dev Biol* 2002;241:106–16. [PubMed: 11784098]
- Kanzler B, Foreman RK, Labosky PA, Mallo M. BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. *Development* 2000;127:1095–104. [PubMed: 10662648]
- Kim HJ, Rice DP, Kettunen PJ, Thesleff I. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. *Development* 1998;125:1241–51. [PubMed: 9477322]
- Kim YJ, Kim HN, Park EK, Lee BH, Ryoo HM, Kim SY, Kim IS, Stein JL, Lian JB, Stein GS, van Wijnen AJ, Choi JY. The bone-related Zn finger transcription factor Osterix promotes proliferation of mesenchymal cells. *Gene* 2006;366:145–51. [PubMed: 16314050]
- Kingsley DM, Bland AE, Grubber JM, Marker PC, Russell LB, Copeland NG, Jenkins NA. The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily. *Cell* 1992;71:399–410. [PubMed: 1339316]
- Kleber M, Lee HY, Wurdak H, Buchstaller J, Riccomagno MM, Ittner LM, Suter U, Epstein DJ, Sommer L. Neural crest stem cell maintenance by combinatorial Wnt and BMP signaling. *J Cell Biol* 2005;169:309–20. [PubMed: 15837799]
- Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M. Targeted Disruption of *Cbfa1* Results in a Complete Lack of Bone Formation owing to Maturation Arrest of Osteoblasts. *Cell* 1997;89:755–764. [PubMed: 9182763]
- Liu Y, Helms AW, Johnson JE. Distinct activities of *Msx1* and *Msx3* in dorsal neural tube development. *Development* 2004;131:1017–1028. [PubMed: 14973289]
- Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D, Marie PJ. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. *J Clin Invest* 1998;101:1310–7. [PubMed: 9502772]
- Lu X, Gilbert L, He X, Rubin J, Nanes MS. Transcriptional regulation of the osterix (*Osx*, *Sp7*) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. *J Biol Chem* 2006;281:6297–306. [PubMed: 16410254]
- Lumsden AG. Spatial organization of the epithelium and the role of neural crest cells in the initiation of the mammalian tooth germ. *Development* 1988;103(Suppl):155–69. [PubMed: 3250849]
- Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. *Genes Dev* 1995;9:2808–20. [PubMed: 7590255]
- Lyons GE, Houzelstein D, Sassoon D, Robert B, Buckingham ME. Multiple sites of *Hox-7* expression during mouse embryogenesis: comparison with retinoic acid receptor mRNA localization. *Mol Reprod Dev* 1992;32:303–14. [PubMed: 1353971]
- MacKenzie A, Ferguson M, Sharpe P. Expression patterns of the homeobox gene, *Hox-8*, in the mouse embryo suggest a role in specifying tooth initiation and shape. *Development* 1992;115:403–420. [PubMed: 1358591]
- Mackenzie A, Leeming G, Jowett A, Ferguson M, Sharpe P. The homeobox gene *Hox 7.1* has specific regional and temporal expression patterns during early murine craniofacial embryogenesis, especially tooth development in vivo and in vitro. *Development* 1991;111:269–285. [PubMed: 1680043]
- Mansukhani A, Bellosta P, Sahni M, Basilico C. Signaling by Fibroblast Growth Factors (FGF) and Fibroblast Growth Factor Receptor 2 (FGFR2)-activating Mutations Blocks Mineralization and Induces Apoptosis in Osteoblasts. *J Cell Biol* 2000;149:1297–1308. [PubMed: 10851026]
- Mbalaviele G, Sheikh S, Stains JP, Salazar VS, Cheng SL, Chen D, Civitelli R. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. *J Cell Biochem* 2005;94:403–18. [PubMed: 15526274]
- Meyers EN, Lewandoski M, Martin GR. An *Fgf8* mutant allelic series generated by Cre- and Flp-mediated recombination. *Nat Genet* 1998;18:136–41. [PubMed: 9462741]
- Min H, Danilenko DM, Scully SA, Bolon B, Ring BD, Tarpley JE, DeRose M, Simonet WS. *Fgf-10* is required for both limb and lung development and exhibits striking functional similarity to *Drosophila* branchless. *Genes Dev* 1998;12:3156–61. [PubMed: 9784490]


- Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ. Targeted disruption of the Wnt2 gene results in placentation defects. *Development* 1996;122:3343–53. [PubMed: 8951051]
- Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ, Losken HW, Mulliken JB, Guttmacher AE, Wilroy RS, Clarke LA, Hollway G, Ades LC, Haan EA, Mulley JC, Cohen MM Jr, Bellus GA, Francomano CA, Moloney DM, Wall SA, Wilkie AO, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. *Am J Hum Genet* 1997;60:555–64. [PubMed: 9042914]
- Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrughe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* 2002;108:17–29. [PubMed: 11792318]
- Newberry EP, Latifi T, Towler DA. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. *Biochemistry* 1998;37:16360–8. [PubMed: 9819228]
- Noden DM. The role of the neural crest in patterning of avian cranial skeletal, connective, and muscle tissues. *Dev Biol* 1983;96:144–65. [PubMed: 6825950]
- Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. *Proc Natl Acad Sci U S A* 1998;95:5672–7. [PubMed: 9576942]
- Otto F, Lubbert M, Stock M. Upstream and downstream targets of RUNX proteins. *J Cell Biochem* 2003;89:9–18. [PubMed: 12682904]
- Robert B, Sassoon D, Jacq B, Gehring W, Buckingham M. Hox-7, a mouse homeobox gene with a novel pattern of expression during embryogenesis. *Embo J* 1989;8:91–100. [PubMed: 2565810]
- Ryoo HM, Hoffmann HM, Beumer T, Frenkel B, Towler DA, Stein GS, Stein JL, van Wijnen AJ, Lian JB. Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. *Mol Endocrinol* 1997;11:1681–94. [PubMed: 9328350]
- Saga Y, Miyagawa-Tomita S, Takagi A, Kitajima S, Miyazaki J, Inoue T. MesP1 is expressed in the heart precursor cells and required for the formation of a single heart tube. *Development* 1999;126:3437–47. [PubMed: 10393122]
- Santagati F, Rijli FM. Cranial neural crest and the building of the vertebrate head. *Nat Rev Neurosci* 2003;4:806–18. [PubMed: 14523380]
- Sasaki T, Ito Y, Bringas P Jr, Chou S, Urata MM, Slavkin H, Chai Y. TGFbeta-mediated FGF signaling is crucial for regulating cranial neural crest cell proliferation during frontal bone development. *Development* 2006;133:371–81. [PubMed: 16368934]
- Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. *Nat Genet* 2000;24:391–5. [PubMed: 10742104]
- Satokata I, Maas R. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. *Nat Genet* 1994;6:348–56. [PubMed: 7914451]
- Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. *Genes Cells* 2001;6:851–6. [PubMed: 11683913]
- Solloway MJ, Dudley AT, Bikoff EK, Lyons KM, Hogan BL, Robertson EJ. Mice lacking Bmp6 function. *Dev Genet* 1998;22:321–39. [PubMed: 9664685]
- Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* 1999;21:70–1. [PubMed: 9916792]
- Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. *J Cell Sci* 2006;119:1283–96. [PubMed: 16522681]
- Suzuki N, Labosky PA, Furuta Y, Hargett L, Dunn R, Fogo AB, Takahara K, Peters DM, Greenspan DS, Hogan BL. Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by Bmp1, a mammalian gene related to Drosophila tolloid. *Development* 1996;122:3587–95. [PubMed: 8951074]

- Tadic T, Dodig M, Erceg I, Marijanovic I, Mina M, Kalajzic Z, Velonis D, Kronenberg MS, Kosher RA, Ferrari D, Lichtler AC. Overexpression of Dlx5 in chicken calvarial cells accelerates osteoblastic differentiation. *J Bone Miner Res* 2002;17:1008–14. [PubMed: 12054155]
- Theiler, K. The house mouse: atlas of embryonic development. Springer-Verlag; New York Inc., New York: 1989. p. 178
- Trainor PA, Krumlauf R. Patterning the cranial neural crest: hindbrain segmentation and Hox gene plasticity. *Nat Rev Neurosci* 2000;1:116–24. [PubMed: 11252774]
- Tribulo C, Aybar MJ, Nguyen VH, Mullins MC, Mayor R. Regulation of Msx genes by a Bmp gradient is essential for neural crest specification. *Development* 2003;130:6441–6452. [PubMed: 14627721]
- Wang W, Chen X, Xu H, Lufkin T. Msx3: a novel murine homologue of the Drosophila msh homeobox gene restricted to the dorsal embryonic central nervous system. *Mech Dev* 1996;58:203–15. [PubMed: 8887328]
- Wilkie AO, Morriss-Kay GM. Genetics of craniofacial development and malformation. *Nat Rev Genet* 2001;2:458–68. [PubMed: 11389462]
- Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev* 1995;9:2105–16. [PubMed: 7657163]
- Xu X, Bringas P Jr, Soriano P, Chai Y. PDGFR-alpha signaling is critical for tooth cusp and palate morphogenesis. *Dev Dyn* 2005;232:75–84. [PubMed: 15543606]
- Yan C, Wang P, DeMayo J, DeMayo FJ, Elvin JA, Carino C, Prasad SV, Skinner SS, Dunbar BS, Dube JL, Celeste AJ, Matzuk MM. Synergistic roles of bone morphogenetic protein 15 and growth differentiation factor 9 in ovarian function. *Mol Endocrinol* 2001;15:854–66. [PubMed: 11376106]
- Yoshizawa T, Takizawa F, Iizawa F, Ishibashi O, Kawashima H, Matsuda A, Endo N, Kawashima H. Homeobox protein MSX2 acts as a molecular defense mechanism for preventing ossification in ligament fibroblasts. *Mol Cell Biol* 2004;24:3460–72. [PubMed: 15060165]
- Yu K, Xu J, Liu Z, Susic D, Shao J, Olson EN, Towler DA, Ornitz DM. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. *Development* 2003;130:3063–3074. [PubMed: 12756187]
- Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* 1996;122:2977–86. [PubMed: 8898212]
- Zhang H, Hu G, Wang H, Sciacvolino P, Iler N, Shen MM, Abate-Shen C. Heterodimerization of Msx and Dlx homeoproteins results in functional antagonism. *Mol Cell Biol* 1997;17:2920–32. [PubMed: 9111364]
- Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003a;425:836–41. [PubMed: 14574412]
- Zhang Z, Song Y, Zhang X, Tang J, Chen J, Chen Y. Msx1/Bmp4 genetic pathway regulates mammalian alveolar bone formation via induction of Dlx5 and Cbfa1. *Mech Dev* 2003b;120:1469–79. [PubMed: 14654219]



**Fig. 1.** *Msx1* and *Msx2* are critical regulators for calvarial morphogenesis. Superior, side and base views of newborn skull preparations stained with Alcian blue and Alizarin Red (red= bone; blue= cartilage). (A–F) In the *Msx1*<sup>-/-</sup> mice, there is a large gap between the two frontal bones in the superior view (arrow) and side view (yellow dotted line) of the skull. (G–L) In *Msx1*<sup>-/-</sup>; *Msx2*<sup>+/-</sup> and *Msx1*<sup>+/-</sup>; *Msx2*<sup>-/-</sup> mice, the defect between the two frontal bones is significantly enlarged. (M–O) *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mice show complete agenesis of the calvaria and most of the bony elements of the skull. (als) alisphenoid (BS) basisphenoid (eo) exoccipital (fr) frontal (ip) interparietal (ma) mandible (mx) maxilla (na) nasal (pmx) premaxilla (pr) parietal (PS) presphenoid (so) supraoccipital (sq) squamosal (tym) tympanic.






**Fig. 2.** Msx1 and Msx2 are co-expressed in the prospective frontal primordium but not the prospective parietal primordium during their initiation. (A,B) After X-gal staining of *Wnt1-Cre;R26R* and *Mesp1-Cre;R26R* mice at E10.5, neural crest cells (arrows) and mesoderm mesenchyme (broken line) are clearly labeled separately with a distinct boundary. (C-F) Whole mount *in situ* hybridization of *Msx1* and *Msx2* at E10.5 and E11.5. The expression of *Msx1* and *Msx2* (arrows) are restricted to the CNC cell domain, with no expression in the mesoderm mesenchyme domain (broken lines). (G, I) Alkaline phosphatase staining of the horizontal section of the calvaria. Frontal and parietal primordia are stained blue. Open box is enlarged in I. (H, J) X-gal staining of the horizontal section of the *Wnt1-Cre;R26R* embryos. CNC-



derived mesenchyme is stained blue. Open box is enlarged in J. (K–P) *In situ* hybridization of *Msx1* (K) and *Msx2* (L) in the horizontal section of the calvarial primordium at E12.5. Open bars indicate the section planes in M (*Msx1* in the frontal primordium), N (*Msx1* in the parietal primordium), O (*Msx2* in the parietal primordium), and P (*Msx2* in the parietal primordium). Arrows indicate the expression of *Msx1* and *Msx2*. (Q) Whole mount alkaline phosphatase staining at E12.5. Both frontal (Fr) and parietal primordia (Pa) are positive. (R,S) Whole mount *in situ* hybridization of *Dlx5* and *Osterix* at E12.5. The frontal primordium expresses both *Dlx5* and *Osterix* (arrows) but the parietal primordium does not. (T) Skeletal staining at E14.0 reveals the formation of the frontal bone (Fr) and the lack of any parietal bone staining. (U) Skeletal staining at E14.5 shows that the frontal bone (Fr) has developed further than the parietal bone (Pa).




**Fig. 3.**


Compromised frontal primordium in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos. Time course showing the development of the frontal primordium in wild type, *Msx1*<sup>-/-</sup>, and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. (A–C) At E11.5, there is no obvious difference in cell density in the presumptive frontal primordium (\*) between wild type and mutant littermates. (D–F) At E12.5, the mesenchyme forms a condensation (double arrow) in both wild type and the *Msx1*<sup>-/-</sup> mutant. The *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> embryos do not have a frontal bone primordium. (G–I) At E14.5, bone matrix is visible (arrow) within the frontal bone primordium of the wild type and *Msx1*<sup>-/-</sup> samples. In the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutants, bone matrix fails to form (arrow). (J–L) At E16.5, frontal bone formation is evident in the wild type and the *Msx1*<sup>-/-</sup> sample (double arrow) with the trabecular

structure (T). There is no bone matrix in the *Msx1*<sup>-/-</sup>; *Msx2*<sup>-/-</sup> mutant, but there is an ectopic structure at the roof of the orbital cavity comprised of condensed mesenchymal cells (double arrows).



**Fig. 4.**


CNC cell migration is unaffected in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. LacZ staining of Wnt1-Cre;R26R (A,B,E) and Wnt1-Cre;R26R;*Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> (C,D,F) mice. (A–D) At E10.5, CNC cells have populated the first branchial arch and the frontonasal process, as indicated by positive  $\beta$ -gal staining (blue color). The CNC that contributes to the development of frontal bone primordium has migrated above the developing eye (arrowhead). The eye (e) is highlighted by a dotted white line. (FB) forebrain (MB) midbrain (Max) maxillary prominence (E–F) Cross-sections of E12.5 heads from wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. CNC-derived mesenchyme in the putative frontal primordium is outlined with broken lines. Inserts show the enlarged CNC-derived frontal primordium (arrow). White open arrow points to the apical expansion of CNC cells (E).



**Fig. 5.** Failure of osteogenic progenitor cell differentiation in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. Alkaline phosphatase staining and in situ hybridizations of *Fgfr2*, *Dlx5*, *Runx2*, and *Osterix* in wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice at E12.5, E14.5 and E16.5. (A–E) Well-defined frontal primordium with alkaline phosphatase (ALPase) activity and expression of *Fgfr2*, *Dlx5*, *Runx2*, and *Osterix* in wild type mice at E12.5. (F–J) Osteogenic markers were not detected in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant at E12.5. (K–O) At E14.5, frontal primordium with osteogenic differentiation markers expression expanded in the wild type mice. (P–T) None of the osteogenic markers expressed in the wild type frontal primordium were detected in the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mutant. (U,X) Side view (and top views) of the skeletal staining of E16.5




head shows that the orbital portion of the frontal bone is formed in the  $Msx1^{+/-};Msx2^{+/-}$  mutant with exencephaly but not in the  $Msx1^{-/-};Msx2^{-/-}$  mutant. The black line indicates the section plane shown in V and Y. (V, Y) Coronal section of the frontal bone. The box in V and Y is shown enlarged in the insert. (W,Z) Alkaline phosphatase staining of the coronal section of the frontal primordium (box, enlarged in insert). The alkaline phosphatase activity is visualized with blue stain in the  $Msx1^{+/-};Msx2^{+/-}$  mice at E12.5 (W). Notice the lack of alkaline phosphatase staining (blue) in the presumptive frontal primordium region of the  $Msx1^{-/-};Msx2^{-/-}$  mice (Z). Fr: frontal bone, Mx: Maxillary, Pa: parietal bone, Sq: squamous bone, Zy: zygomatic arch.




**Fig. 6.** Artificially-enhanced cell density fails to rescue the differentiation defect of the CNC-derived mesenchymal cells in *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. (A–D) Phase contrast light microscopy of micromass cultures of frontal primordium mesenchymal cells from wild type, *Msx1*<sup>-/-</sup>, *Msx2*<sup>-/-</sup> and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> mice. Arrows indicate nodule-like masses. (E–H) Whole-mount Alcian blue and Alizarin Red staining of the micromass cultures (cartilage in blue and bone in red). White arrows indicate the nodule-like masses. (I–L) Cross-sections of the samples in E–H. Staining of the wild type, *Msx1*<sup>-/-</sup>, and *Msx2*<sup>-/-</sup> samples reveal trabecular-like structures (arrow) and condensed multiple layer structure (black box, enlarged image at the lower right insert). Cartilage development (in blue) and chondrocytes (white box, enlarged at the upper right inset). In the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> sample, there is no detectable bone or cartilage development. The black and white-boxed area (enlarged images are shown as inserts) does not contain any osteocytes or chondrocytes. (M–P) Von Kossa staining of micromass cultures reveals calcium deposition. (Q–T) Alkaline phosphatase activity (blue staining) in monolayer cultures of CNC-derived mesenchymal cells.





**Fig. 7.** Ectopic expression of Runx2 rescued the differentiation defect of the *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> frontal mesenchyme. (A–C) Merged images of phase contrast light microscopy and GFP fluorescence. (D–F) Alkaline phosphatase staining of wild type and *Msx1*<sup>-/-</sup>;*Msx2*<sup>-/-</sup> frontal mesenchyme culture after transfection. (G) Real-time PCR confirmed the ectopic expression of Runx2. Gene expression was normalized using  $\beta$ -actin. Ribosomal protein L10a was used as negative control.



**Fig. 8.**

Bmp signaling pathway is largely unaltered. (A–L) Whole mount *in situ* hybridization of *Bmp2*, *Bmp4*, and *Bmp7* of E10.5 and E12.5 wild type mice. The expression in the whiskers and branchial arches (\*) served as control. *Bmp4* is expressed in the frontal and midbrain region at E10.5 (arrow and arrowhead) and the frontal primordium and midbrain at E12.5 (arrow and arrowhead). *Bmp2* and *Bmp7* were not detected in the frontal primordium at E12.5. (M–Q) *In situ* hybridization of *Bmp4* in sections from the presumptive frontal primordium at E11.5. *Bmp4* is expressed in the future frontal primordium in wild type, *Msx1<sup>-/-</sup>*, *Msx2<sup>-/-</sup>*, and *Msx1<sup>-/-</sup>;Msx2<sup>-/-</sup>* samples (arrow). The expression of *Bmp4* in the brain (\*) served as control. (R–V) Immunostaining of phospho-Smad1/Smad5/Smad8 in the presumptive frontal



primordium at E11.5. Phosphorylation of Smad1/5/8 is detected in all samples (arrow). Insert: enlarged box area.